Among adults and adolescents with cystic fibrosis starting triple therapy for the first time, inflammatory markers fell and ...
Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...
Please provide your email address to receive an email when new articles are posted on . Sweat chloride did not significantly differ between baseline and day 28 of triple therapy in this patient ...
Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial is ...
SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...
(WNDU) - Cystic fibrosis is an inherited disease that affects the lungs, the pancreas, and other organs. There is no cure. New medications have come a long way to improve the symptoms for many, but ...
Researchers conducted a phase 3b open-label trial at multiple sites in Australia and the European Union to assess the effect of elexacaftor-tezacaftor-ivacaftor, an approved medication for cystic ...
Researchers created a highly efficient gene-editing method that fixes multiple DNA mutations in a single step. The breakthrough could revolutionize genetic medicine by making treatments for complex ...
A cystic fibrosis vest is a therapeutic tool. When worn, it provides compressions similar to manual chest percussions. Wearing the vest can help loosen sticky secretions so that a person can more ...
A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech ...
The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation ...